share_log

iBio Inc | 10-K: FY2024 Annual Report

iBio Inc | 10-K: FY2024 Annual Report

iBio Inc | 10-K：2024財年年報
美股SEC公告 ·  2024/09/20 13:19

Moomoo AI 已提取核心訊息

iBio Inc. reported financial results for fiscal year 2024, with revenue of $0.2 million compared to no revenue in FY2023. Net loss from continuing operations decreased to $15.4 million from $29.3 million in the prior year, while total net loss including discontinued operations was $24.9 million versus $65.0 million. Operating expenses declined 42% to $16.9 million due to reduced R&D and G&A costs.The company completed its transformation into an AI-driven antibody discovery company, divesting its CDMO facility in Texas for $8.5 million and settling related debt obligations. Strategic achievements included entering collaborations with AstralBio for cardiometabolic diseases, selling PD-1 assets to Otsuka, and raising approximately $15 million through a private placement.Looking ahead, iBio is advancing its preclinical pipeline leveraging its AI technology stack, with positive data for three immuno-oncology candidates. The company held $14.4 million in cash and equivalents as of June 30, 2024, expected to fund operations into Q1 FY2026. Management is evaluating options to extend cash runway through potential asset sales, licensing deals and additional capital raises.
iBio Inc. reported financial results for fiscal year 2024, with revenue of $0.2 million compared to no revenue in FY2023. Net loss from continuing operations decreased to $15.4 million from $29.3 million in the prior year, while total net loss including discontinued operations was $24.9 million versus $65.0 million. Operating expenses declined 42% to $16.9 million due to reduced R&D and G&A costs.The company completed its transformation into an AI-driven antibody discovery company, divesting its CDMO facility in Texas for $8.5 million and settling related debt obligations. Strategic achievements included entering collaborations with AstralBio for cardiometabolic diseases, selling PD-1 assets to Otsuka, and raising approximately $15 million through a private placement.Looking ahead, iBio is advancing its preclinical pipeline leveraging its AI technology stack, with positive data for three immuno-oncology candidates. The company held $14.4 million in cash and equivalents as of June 30, 2024, expected to fund operations into Q1 FY2026. Management is evaluating options to extend cash runway through potential asset sales, licensing deals and additional capital raises.
iBio Inc. 發佈了2024財年的財務結果，營業收入爲$20萬，而2023財年沒有營業收入。持續經營的淨虧損從去年的$2930萬減至$1540萬，包含終止經營的總淨虧損爲$2490萬，而去年的虧損爲$6500萬。由於研發和一般管理費用減少，營業費用下降了42%，降至$1690萬。該公司完成了向人工智能驅動的抗體發現公司的轉型，出售了位於德克薩斯州的CMO設施，獲得$850萬，並解決了相關債務義務。戰略成就包括與AstralBio在心代謝疾病方面的合作，向大冢出售PD-1資產，以及通過定向增發籌集了大約$1500萬。展望未來，iBio正在利用其人工智能技術棧推進其臨牀前項目，併爲三個免疫腫瘤候選藥物提供了積極數據。截止2024年6月30日，公司持有現金及其等價物$1440萬，預計可以支持運營到2026財年第一季度。管理層正在評估通過潛在的資產銷售、許可交易和額外融資來延長現金使用期限的期權。
iBio Inc. 發佈了2024財年的財務結果，營業收入爲$20萬，而2023財年沒有營業收入。持續經營的淨虧損從去年的$2930萬減至$1540萬，包含終止經營的總淨虧損爲$2490萬，而去年的虧損爲$6500萬。由於研發和一般管理費用減少，營業費用下降了42%，降至$1690萬。該公司完成了向人工智能驅動的抗體發現公司的轉型，出售了位於德克薩斯州的CMO設施，獲得$850萬，並解決了相關債務義務。戰略成就包括與AstralBio在心代謝疾病方面的合作，向大冢出售PD-1資產，以及通過定向增發籌集了大約$1500萬。展望未來，iBio正在利用其人工智能技術棧推進其臨牀前項目，併爲三個免疫腫瘤候選藥物提供了積極數據。截止2024年6月30日，公司持有現金及其等價物$1440萬，預計可以支持運營到2026財年第一季度。管理層正在評估通過潛在的資產銷售、許可交易和額外融資來延長現金使用期限的期權。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

獨立文件2  查看翻譯

獨立文件3  查看翻譯

獨立文件4  查看翻譯

獨立文件5  查看翻譯

獨立文件6  查看翻譯

獨立文件7  查看翻譯

獨立文件8  查看翻譯

獨立文件9  查看翻譯

獨立文件10  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    相關股票 相關股票
    代碼 迷你走勢 最新價
    Dogwood Therapeutics
    DWTX
    -- 3.150
    Camp4 Therapeutics
    CAMP
    -- 6.540
    Channel Therapeutics
    CHRO
    -- 2.660
    Allakos
    ALLK
    -- 1.110
    Nutriband
    NTRB
    -- 5.210
    解鎖完整榜單
    熱門討論
    特朗普2.0時代開啓，全球股市新風口在哪裏？
    ▪️加密貨幣政策能否利好crypto? ▪️關稅政策能否利好中概等海外資產？ ▪️在特朗普政策下，有哪些投資機會值得關注？ 展开
    離川普上臺只有7天了～